non-adjuvanted HSV formulation 3

Non-adjuvanted HSV formulation 3 is an investigational vaccine candidate developed for the prevention or treatment of herpes simplex virus (HSV) infection, specifically targeting individuals with recurrent genital herpes. This vaccine is a non-adjuvanted formulation, meaning it does not include an immune-boosting adjuvant component. It was evaluated in clinical trials as part of a targeted immunotherapy approach against HSV, with participants receiving two intramuscular doses on days 1 and 29. The primary mechanism involves stimulating the immune system to recognize and respond to HSV antigens, aiming to reduce the frequency or severity of recurrent genital herpes episodes. The development program was led by GSK (GlaxoSmithKline). In phase 2 clinical trials (TH HSV REC-003), the vaccine did not meet its primary efficacy endpoint—time to first confirmed episode of recurrent genital herpes—and further development has been discontinued[6][7].

Other names

non-adjuvanted HSV formulation 3HSV-targeted immunotherapyHSVTI